- 3.4Impact Factor
- 9.9CiteScore
- 20 daysTime to First Decision
Vaccines, Volume 8, Issue 3
September 2020 - 216 articles
Cover Story: Zika virus (ZIKV) is the etiological agent responsible for a range of debilitating and often lifelong birth defects collectively termed congenital Zika syndrome (CZS). Although the ZIKV pandemic has subsided, ZIKV continues to be a burden, with 87 countries and territories now displaying autochthonous ZIKV transmission and no commercial vaccine is currently available. This paper uses a recently designed flavivirus chimeric platform comprising the backbone of an Australian mosquito virus, Binjari virus, to generate a ZIKV vaccine candidate named BinJ/ZIKV-prME. This vaccine, administered unadjuvanted and as a single dose, protected against fetal ZIKV infection and did not cause antibody-dependent enhancement of dengue infection and disease in mice. BinJ/ZIKA-prME thus emerges as a potential vaccine candidate for the prevention of CSZ. View this paper.
- Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
- You may sign up for email alerts to receive table of contents of newly released issues.
- PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.
Articles
There are no articles in this issue yet.
Get Alerted
Add your email address to receive forthcoming issues of this journal.
Vaccines - ISSN 2076-393X